St. Joseph Cancer Center - Clinical Trials: Breast
  

Early Stage:

  • None currently

Stage 0, I, or II:

  • RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation vs Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer

T1-3, Node Negative:

  • NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide to Four Cycles of Adriamycin and Cyclophosphamide in Patients With Node-Negative Breast Cancer

  • CTSU 40101: Randomized Study, Cyclosphosphamide and Doxorubicin (4 vs. 6 Cycles) vs. Paclitaxel (12 Weeks vs. 18 Weeks) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial, Phase III

  • CTSU PACCT-1: Program for the Assessment of Clinical Trial Tests (PACCT-1):
    Trial Assigning Individualized Options for Treatment: The TAYLORx Trial

Stage I, II, III:

  • SWOG 0221: Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer.

  • SWOG 0230: Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.

  • SWOG 0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

  • CTSU 24-02: Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer. (SOFT Trial)

  • NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

  • NASBP B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens

Stage II, III:

  • CTSU MA.27: A Randomized Phase III Trial of Exemestane vs Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

  • CTSU MA.27B: The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer

  • CTSU MA.27D: The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to CTSU MA.27

Stage IV:

  • SWOG 0226: Phase III Randomized Trail of Anastrozole vs Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer.

  • NSABP B-37: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-regional Relapse of Breast Cancer

  • SWOG 0500: A Randomized Phase III Trial to test the Strategy of Changing therapy Versus Maintaining Therapy for Metastatic Breast cancer Patients who have Elevated Circulating Tumor Cells at First Follow-Up Assessment

  • CTSU E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer

For more information on the above clinical trials: Cheryl Patz, RN, OCN, CCRC, 360.715.4133

Return to previous page

Cancer Services